mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
2e-05 |
mRNA |
momelotinib |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
2e-05 |
mRNA |
BRD-K45681478 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
3e-05 |
mRNA |
triazolothiadiazine |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
3e-05 |
mRNA |
PF-184 |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
3e-05 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
4e-05 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
5e-05 |
mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
5e-05 |
mRNA |
Cerulenin |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
5e-05 |
mRNA |
tivantinib |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
6e-05 |